Item Type | Name |
Academic Article
|
Methods for production of monoclonal antibodies with specificity for human lung cancer cells.
|
Academic Article
|
Herpes zoster and small cell bronchogenic carcinoma.
|
Academic Article
|
Evaluation of response to chemotherapy with fiberoptic bronchoscopy in non-small cell lung cancer.
|
Academic Article
|
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23).
|
Academic Article
|
Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer.
|
Academic Article
|
Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience.
|
Academic Article
|
Abdominal computed tomography in small cell lung cancer: assessment of extent of disease and response to therapy.
|
Academic Article
|
Lack of efficacy of high-dose methotrexate by 30-hour infusion in patients with progressive small cell carcinoma of the lung.
|
Academic Article
|
The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes.
|
Academic Article
|
Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response.
|
Academic Article
|
Small cell lung cancer 1973-1983: early progress and recent obstacles.
|
Academic Article
|
Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy.
|
Academic Article
|
Perirectal infections in patients with small cell lung cancer.
|
Academic Article
|
Possible enhancement of vincristine neuropathy by VP-16.
|
Academic Article
|
Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic carcinoma. Severe pulmonary toxicity from q 3 weekly mitomycin C.
|
Academic Article
|
Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy.
|
Academic Article
|
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
|
Academic Article
|
Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines.
|
Academic Article
|
New treatment agents for advanced small cell and non-small cell lung cancer.
|
Academic Article
|
A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study.
|
Academic Article
|
Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity.
|
Academic Article
|
Combined modality therapy in small cell lung cancer.
|
Academic Article
|
Secondary screening system for preclinical testing of human lung cancer therapies.
|
Academic Article
|
The treatment of non-small cell lung cancer: current perspectives and controversies, future directions.
|
Academic Article
|
Controversies in the nonsurgical treatment of stage III non-small cell lung cancer.
|
Academic Article
|
Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl.
|
Academic Article
|
Clinical experiences with carboplatin (paraplatin) in lung cancer.
|
Academic Article
|
The role of routine chest radiotherapy in small-cell lung cancer. An issue of timing and stage.
|
Academic Article
|
Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer.
|
Academic Article
|
Smoking abstinence and small cell lung cancer survival. An association.
|
Academic Article
|
Influence of histologic subtype of small cell carcinoma of the lung on clinical presentation, response to therapy, and survival.
|
Academic Article
|
Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: an active drug combination with major nonhematologic toxicity.
|
Academic Article
|
Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer.
|
Academic Article
|
Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung.
|
Academic Article
|
Phase II trial of cisplatin in small cell carcinoma of the lung.
|
Academic Article
|
Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer.
|
Academic Article
|
Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients.
|
Academic Article
|
Small-cell carcinoma of lung: reinduction therapy after late relapse.
|
Academic Article
|
Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites.
|
Academic Article
|
Novel bradykinin antagonist dimers for the treatment of human lung cancers.
|
Academic Article
|
Combination paclitaxel and platinum in the treatment of lung cancer: US experience.
|
Academic Article
|
Future directions in therapeutic approaches for small cell lung cancer.
|
Academic Article
|
5th I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, Switzerland.
|
Academic Article
|
The emerging role of gemcitabine in lung cancer: part I.
|
Academic Article
|
Streptozotocin in advanced small cell bronchogenic carcinoma: an ineffective nonmyelosuppressive agent.
|
Academic Article
|
Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
|
Academic Article
|
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
|
Academic Article
|
Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.
|
Academic Article
|
Overview of chemotherapy for small cell lung cancer.
|
Academic Article
|
A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer.
|
Academic Article
|
The emerging role of gemcitabine in lung cancer.
|
Academic Article
|
Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer.
|
Academic Article
|
Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth.
|
Academic Article
|
Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?
|
Academic Article
|
Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
|
Academic Article
|
New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma.
|
Academic Article
|
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.
|
Academic Article
|
New therapeutic strategies for lung cancer: biology and molecular biology come of age.
|
Academic Article
|
Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha 16.
|
Academic Article
|
New combinations in the treatment of lung cancer: a time for optimism.
|
Academic Article
|
Altered HOX and WNT7A expression in human lung cancer.
|
Academic Article
|
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
|
Academic Article
|
The inherited nature of lung cancer: a pilot study.
|
Academic Article
|
Chemotherapy rather than demeclocycline for inappropriate secretion of antidiuretic hormone.
|
Academic Article
|
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
|
Academic Article
|
Current therapy of small cell lung cancer.
|
Academic Article
|
Growth rates of small cell bronchogenic carcinomas.
|
Academic Article
|
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
|
Academic Article
|
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
|
Academic Article
|
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.
|
Academic Article
|
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
|
Academic Article
|
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
|
Academic Article
|
What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer?
|
Academic Article
|
Central nervous system metastases in small cell bronchogenic carcinoma.
|
Academic Article
|
Pemetrexed as a single agent in the therapy of advanced lung cancer.
|
Academic Article
|
Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
|
Academic Article
|
Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.
|
Academic Article
|
HER2/neu expression in malignant lung tumors.
|
Academic Article
|
Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
|
Academic Article
|
Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?
|
Academic Article
|
Lung cancer. Introduction.
|
Academic Article
|
An update on North American randomized studies in non-small cell lung cancer.
|
Academic Article
|
Triplet chemotherapy combinations with new agents: is there a rationale?
|
Academic Article
|
Chemotherapy for elderly patients with advanced non-small-cell lung cancer.
|
Academic Article
|
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
|
Academic Article
|
Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo.
|
Academic Article
|
Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.
|
Academic Article
|
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
|
Academic Article
|
Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction.
|
Academic Article
|
The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer.
|
Academic Article
|
The potential role of proteasome inhibitors in the treatment of lung cancer.
|
Academic Article
|
A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal immunoadsorption.
|
Academic Article
|
Chemoprevention of lung cancer--from biology to clinical reality.
|
Academic Article
|
Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
|
Academic Article
|
Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
|
Academic Article
|
Platinums in lung cancer: sufficient or necessary?
|
Academic Article
|
Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
|
Academic Article
|
Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
|
Academic Article
|
Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
|
Academic Article
|
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
|
Academic Article
|
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
|
Academic Article
|
High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia.
|
Academic Article
|
Irradiated nude rat model for orthotopic human lung cancers.
|
Academic Article
|
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
|
Academic Article
|
Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy.
|
Academic Article
|
Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.
|
Academic Article
|
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
|
Academic Article
|
Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
|
Academic Article
|
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
|
Academic Article
|
Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
|
Academic Article
|
Operation for stage IIIa small cell lung cancer?
|
Academic Article
|
Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
|
Academic Article
|
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
|
Academic Article
|
Lack of association between sputum atypia and chronic obstructive pulmonary disease mortality.
|
Academic Article
|
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
|
Academic Article
|
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.
|
Academic Article
|
Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
|
Academic Article
|
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
|
Academic Article
|
Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.
|
Academic Article
|
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
|
Academic Article
|
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
|
Academic Article
|
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
|
Academic Article
|
EGFR testing in lung cancer is ready for prime time.
|
Academic Article
|
Novel therapies for non-small-cell lung cancer: a 2008 update.
|
Academic Article
|
Innovative and future approaches to small cell lung cancer treatment.
|
Academic Article
|
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
|
Academic Article
|
Optimal therapy for elderly patients with early stage non-small cell lung cancer.
|
Academic Article
|
Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
|
Academic Article
|
A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
|
Academic Article
|
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
|
Academic Article
|
The expanding role of cisplatin in the treatment of non-small-cell lung cancer.
|
Academic Article
|
ZEB1-responsive genes in non-small cell lung cancer.
|
Academic Article
|
Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment?
|
Academic Article
|
Advances in small cell bronchogenic carcinoma.
|
Academic Article
|
Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.
|
Academic Article
|
Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk.
|
Academic Article
|
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
|
Academic Article
|
Oral iloprost improves endobronchial dysplasia in former smokers.
|
Academic Article
|
Seminars in oncology. Introduction.
|
Academic Article
|
Epidermal growth factor receptor family in lung cancer and premalignancy.
|
Academic Article
|
Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
|
Academic Article
|
A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.
|
Academic Article
|
Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
|
Academic Article
|
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
|
Academic Article
|
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.
|
Academic Article
|
Non-invasive breath analysis of pulmonary nodules.
|
Academic Article
|
Results of therapeutic cranial irradiation in small cell lung cancer.
|
Academic Article
|
Characteristics of lung cancers harboring NRAS mutations.
|
Academic Article
|
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.
|
Academic Article
|
Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up.
|
Academic Article
|
Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.
|
Academic Article
|
Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.
|
Academic Article
|
Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies.
|
Academic Article
|
Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer.
|
Academic Article
|
New targeted therapies for lung cancer: expectations and reality.
|
Academic Article
|
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
|
Academic Article
|
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties.
|
Academic Article
|
Role of radiation therapy in small cell anaplastic carcinoma of the lung.
|
Academic Article
|
Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response.
|
Academic Article
|
Small cell carcinoma presenting as an extrapulmonary neoplasm: sites of origin and response to chemotherapy.
|
Academic Article
|
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC).
|
Academic Article
|
Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer.
|
Academic Article
|
High-dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lung.
|
Academic Article
|
Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer.
|
Academic Article
|
Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
|
Academic Article
|
Prophylactic cranial irradiation for patients with small-cell lung cancer.
|
Academic Article
|
Irinotecan and platinums in the treatment of non small-cell lung cancer.
|
Academic Article
|
Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer.
|
Academic Article
|
Future directions in clinical research for lung cancer.
|
Academic Article
|
High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum.
|
Academic Article
|
Novel agents in the treatment of lung cancer: conference summary statement.
|
Academic Article
|
European School of Oncology. First Euro-American Forum on Lung Cancer Treatment.
|
Academic Article
|
Small cell lung cancer: etiology, biology, clinical features, staging, and treatment.
|
Academic Article
|
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
|
Academic Article
|
Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
|
Academic Article
|
NCI-Navy Medical Oncology Branch cell line data base.
|
Academic Article
|
Effects of neuropeptides on human lung and breast cancer cells.
|
Academic Article
|
New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed.
|
Academic Article
|
Carboxypeptidase M. Variable expression in normal human lung and inactivation in lung cancer.
|
Academic Article
|
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
|
Academic Article
|
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
|
Academic Article
|
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
|
Academic Article
|
A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
|
Academic Article
|
Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity.
|
Academic Article
|
Immune therapy for lung cancer: are we getting closer?
|
Academic Article
|
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
|
Academic Article
|
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort.
|
Academic Article
|
Triplet combination chemotherapy and targeted therapy regimens.
|
Academic Article
|
Maximum tolerated dose for low-dose continuous infusion cisplatin.
|
Academic Article
|
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
|
Academic Article
|
Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.
|
Academic Article
|
Growth factors in lung cancer: possible etiologic role and clinical target.
|
Academic Article
|
[State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer].
|
Academic Article
|
Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study.
|
Academic Article
|
Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways.
|
Academic Article
|
Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.
|
Academic Article
|
Serial fiberoptic bronchoscopy during chemotherapy for small cell carcinoma of the lung: early detection of patients at high risk of relapse.
|
Academic Article
|
Bone marrow metastases in small cell carcinoma of the lung: frequency, description, and influence on chemotherapeutic toxicity and prognosis.
|
Academic Article
|
Expression of target molecules in lung cancer: challenge for a new treatment paradigm.
|
Academic Article
|
IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001.
|
Academic Article
|
Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
|
Academic Article
|
Response to thoracic radiotherapy in patients with small cell carcinoma of the lung after failure of combination chemotherapy.
|
Academic Article
|
CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival.
|
Academic Article
|
Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
|
Academic Article
|
Ongoing and future trials of biologic therapies in lung cancer.
|
Academic Article
|
Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column.
|
Academic Article
|
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
|
Academic Article
|
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
|
Academic Article
|
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
|
Academic Article
|
Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
|
Academic Article
|
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
|
Academic Article
|
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.
|
Academic Article
|
A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer.
|
Academic Article
|
Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer.
|
Academic Article
|
Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
|
Academic Article
|
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
|
Academic Article
|
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model.
|
Academic Article
|
Adjuvant chemotherapy for resected non-small-cell lung cancer.
|
Academic Article
|
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.
|
Academic Article
|
Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease.
|
Academic Article
|
Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity.
|
Academic Article
|
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
|
Academic Article
|
First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.
|
Academic Article
|
Anti-growth factor therapy for lung cancer.
|
Academic Article
|
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
|
Academic Article
|
Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium.
|
Academic Article
|
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
|
Academic Article
|
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.
|
Academic Article
|
Adjuvant chemotherapy for non-small cell lung cancer.
|
Academic Article
|
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
|
Academic Article
|
Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.
|
Academic Article
|
Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
|
Academic Article
|
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.
|
Academic Article
|
Diseases desperate grown.
|
Academic Article
|
Review of therapeutic trials of carboplatin in lung cancer.
|
Academic Article
|
The tissue is the issue: personalized medicine for non-small cell lung cancer.
|
Academic Article
|
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).
|
Academic Article
|
A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer.
|
Academic Article
|
Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells.
|
Academic Article
|
Early-stage NSCLC: the role of radiotherapy and systemic therapy.
|
Academic Article
|
MAGE A3 antigen-specific cancer immunotherapeutic.
|
Academic Article
|
Genetic testing for lung cancer: reflex versus clinical selection.
|
Academic Article
|
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
|
Academic Article
|
Classification of lung cancer histology by gold nanoparticle sensors.
|
Academic Article
|
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
|
Academic Article
|
Worldwide overview of the current status of lung cancer diagnosis and treatment.
|
Academic Article
|
Endobronchial miRNAs as biomarkers in lung cancer chemoprevention.
|
Academic Article
|
Origin of human small cell lung cancer.
|
Academic Article
|
Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome?
|
Academic Article
|
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
|
Academic Article
|
Lung cancer in 2013: state of the art therapy for metastatic disease.
|
Academic Article
|
The role of radiation therapy in the treatment of small cell lung cancer.
|
Academic Article
|
Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
|
Academic Article
|
Automated fluorescent analysis for drug-induced cytotoxicity assays.
|
Academic Article
|
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
|
Academic Article
|
Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer.
|
Academic Article
|
Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial.
|
Academic Article
|
Markedly different antibody responses to immunized small cell and non-small cell lung cancer cells.
|
Academic Article
|
Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging.
|
Concept
|
Lung Neoplasms
|
Academic Article
|
Volatile fingerprints of cancer specific genetic mutations.
|
Academic Article
|
The evolution of tumor classification: a role for genomics?
|
Academic Article
|
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
|
Academic Article
|
Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
|
Academic Article
|
Progress in research on screening and genetics in lung cancer.
|
Academic Article
|
Recent clinical advances in lung cancer management.
|
Academic Article
|
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
|
Academic Article
|
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
|
Academic Article
|
Reply to A. Braillon.
|
Academic Article
|
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
|
Academic Article
|
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
|
Academic Article
|
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
|
Academic Article
|
Personalized one-two punches for lung cancer.
|
Academic Article
|
Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
|
Academic Article
|
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.
|
Academic Article
|
Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers.
|
Academic Article
|
Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.
|
Academic Article
|
Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
|
Academic Article
|
Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.
|
Academic Article
|
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
|
Academic Article
|
Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer.
|
Academic Article
|
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
|
Academic Article
|
Scientific Advances in Lung Cancer 2015.
|
Academic Article
|
Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.
|
Academic Article
|
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.
|
Academic Article
|
Clinicopathologic Features of Advanced Squamous NSCLC.
|
Academic Article
|
New and emerging targeted treatments in advanced non-small-cell lung cancer.
|
Academic Article
|
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
|
Academic Article
|
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.
|
Academic Article
|
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer.
|
Academic Article
|
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal?from the Bench.
|
Academic Article
|
Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016.
|
Academic Article
|
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
|
Academic Article
|
The role of irinotecan combined with Cisplatin or Carboplatin in the treatment of advanced non-small-cell lung cancer.
|
Academic Article
|
Current therapeutic approaches in lung cancer.
|
Academic Article
|
Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
|
Grant
|
7TH WORLD CONFERENCE ON LUNG CANCER
|
Grant
|
Lung Cancer Mutation Analysis
|
Grant
|
SPORE in Lung Cancer
|
Academic Article
|
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
|
Academic Article
|
Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
|
Academic Article
|
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
|
Academic Article
|
Small-cell lung cancer: what we know, what we need to know and the path forward.
|
Academic Article
|
Small-cell lung cancer: what we know, what we need to know and the path forward.
|
Academic Article
|
Advances in lung cancer.
|
Academic Article
|
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
|
Academic Article
|
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
|
Academic Article
|
Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
|
Academic Article
|
Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
|
Academic Article
|
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
|
Academic Article
|
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
|
Academic Article
|
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
|
Academic Article
|
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
|
Academic Article
|
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
|
Academic Article
|
Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia.
|
Academic Article
|
Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers.
|
Academic Article
|
Broad-Based Molecular Testing for Lung Cancer: Precisely the Time for Precision.
|
Academic Article
|
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
|
Academic Article
|
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
|
Academic Article
|
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
|
Academic Article
|
Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.
|
Academic Article
|
New Developments in Neoadjuvant Therapy for Lung Cancer.
|
Academic Article
|
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
|
Academic Article
|
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
|
Academic Article
|
A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers.
|
Academic Article
|
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
|
Academic Article
|
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance.
|
Academic Article
|
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
|
Academic Article
|
Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer.
|
Academic Article
|
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
|
Academic Article
|
Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury.
|
Academic Article
|
2020 Innovation-Based Optimism for Lung Cancer Outcomes.
|
Academic Article
|
Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations.
|
Academic Article
|
Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.
|
Academic Article
|
Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer.
|
Academic Article
|
International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.
|
Academic Article
|
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
|
Academic Article
|
Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
|
Academic Article
|
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer.
|
Academic Article
|
Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization.
|
Academic Article
|
Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses.
|
Academic Article
|
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.
|
Academic Article
|
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
|
Academic Article
|
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
|
Academic Article
|
Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit.
|
Academic Article
|
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.
|
Academic Article
|
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
|
Academic Article
|
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.
|
Academic Article
|
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
|
Academic Article
|
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
|
Academic Article
|
Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.
|
Academic Article
|
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
|